World Investment Advisors LLC raised its stake in shares of Geron Co. (NASDAQ:GERN - Free Report) by 10,151.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,029,553 shares of the biopharmaceutical company's stock after acquiring an additional 1,019,510 shares during the period. World Investment Advisors LLC owned approximately 0.17% of Geron worth $4,674,000 as of its most recent SEC filing.
Other institutional investors have also made changes to their positions in the company. National Bank of Canada FI grew its holdings in shares of Geron by 1,200.0% in the second quarter. National Bank of Canada FI now owns 6,500 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 6,000 shares in the last quarter. Readystate Asset Management LP purchased a new position in Geron in the third quarter worth approximately $58,000. Rovin Capital UT ADV purchased a new position in Geron in the third quarter worth approximately $62,000. CIBC Asset Management Inc lifted its stake in Geron by 32.7% in the second quarter. CIBC Asset Management Inc now owns 15,438 shares of the biopharmaceutical company's stock worth $65,000 after acquiring an additional 3,805 shares during the last quarter. Finally, Empowered Funds LLC purchased a new position in Geron in the third quarter worth approximately $67,000. 73.71% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Several brokerages have recently weighed in on GERN. HC Wainwright restated a "buy" rating and set a $9.00 price objective on shares of Geron in a research report on Tuesday. Needham & Company LLC reiterated a "buy" rating and issued a $6.00 price target on shares of Geron in a research report on Friday. Leerink Partners initiated coverage on shares of Geron in a research report on Monday, September 9th. They issued an "outperform" rating and a $7.00 price target for the company. Barclays upgraded shares of Geron to a "strong-buy" rating in a research report on Friday, November 29th. Finally, Leerink Partnrs upgraded shares of Geron to a "strong-buy" rating in a research report on Monday, September 9th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $7.15.
Check Out Our Latest Report on GERN
Geron Price Performance
Shares of NASDAQ:GERN traded down $0.09 on Friday, reaching $3.83. 3,398,333 shares of the company were exchanged, compared to its average volume of 10,137,571. The company has a current ratio of 2.89, a quick ratio of 2.74 and a debt-to-equity ratio of 0.04. Geron Co. has a 1-year low of $1.64 and a 1-year high of $5.34. The firm has a market cap of $2.32 billion, a price-to-earnings ratio of -12.25 and a beta of 0.51. The company has a 50-day moving average of $4.08 and a 200-day moving average of $4.34.
Geron (NASDAQ:GERN - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.05. Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. The business had revenue of $28.27 million for the quarter, compared to analyst estimates of $18.97 million. During the same period in the previous year, the firm earned ($0.08) EPS. The business's revenue for the quarter was up 17138.4% compared to the same quarter last year. Equities analysts forecast that Geron Co. will post -0.25 earnings per share for the current fiscal year.
About Geron
(
Free Report)
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.
Featured Articles
Before you consider Geron, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Geron wasn't on the list.
While Geron currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
